Jennifer Molina

Company: Ribon Therapeutics

Job title: Principal Scientist

Seminars:

Inhibition of PARP7 by RBN-2397 Activates the Type I Interferon Response in Tumors Leading to Robust Antitumor Activity 9:00 am

Explore how PARP7 negatively regulates the type 1 interferon response in cancer cells Delving into discovery, development, and clinical progress of its inhibiton which triggers antitumor immunityRead more

day: Day One